Lung Foundation Australia, in collaboration with the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF), look forward to presenting this webinar: PF / ILD Clinical Trials: Exploring current research and insights into participation.
This live webinar featuring A/Prof Vidya Navaratnam, Respiratory Physician, and Prof. Ian Glaspole, Respiratory & Sleep Disorders Physician, will provide you with an insight into PF/ILD clinical trials.
During this session, we’ll cover:
- What’s new and upcoming in PF/ILD clinical trials
- Insights into what it’s like to take part in a clinical trial and how to get involved
- An overview of the Pulmonary Fibrosis Australasian Clinical Trials (PACT) Network
You’ll also have the opportunity to ask questions and engage in real-time discussions.
Meet our speakers
Associate Professor Vidya Navaratnam
Associate Prof Vidya Navaratnam is a thoracic and lung transplant physician and a trained epidemiologist. Her research interests include using routinely collected health information to conduct large epidemiological studies and target trial emulation. She is also passionate about clinical trials and is principal investigator to commercial and investigator led trials at the Institute for Respiratory Health. A/Prof Navaratnam has international clinical and research experience in lung fibrosis and collaborates closely with other researchers in the CRE-PF.
Professor Ian Glaspole
Prof. Ian Glaspole is a clinician academic, head of the Interstitial lung disease service at the Alfred Hospital, Melbourne and an Adjunct Clinical Professor in the Central and Eastern Clinical School, Monash University. He completed his advanced training in respiratory medicine at the Royal Brompton Hospital in London and his doctoral research at the Alfred Hospital. Shortly after, he established the first dedicated interstitial lung disease service in Australia, at the Alfred Hospital.
He is the current chair of the Pulmonary Fibrosis Australasian Clinical Trials Network (PACT). He has been a chief investigator in five NHMRC grants and an associate investigator in another. His industry sponsored research has garnered over $6 million in funding and he participates as a researcher, consultant and steering committee member to multiple pharmaceutical companies involved in ILD drug development.
He has published 104 peer-reviewed manuscripts, including 3 position statements, with 68 publications in the last five years. He was an author of the pivotal clinical trial demonstrating efficacy of pirfenidone for IPF, published in the New Engl J Med in 2014, and the senior author of the TSANZ position statement on the ILD multi-disciplinary meeting.
This webinar is proudly supported by
